OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Christian U Blank, Minke W Lucas, Richard A. Scolyer, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1696-1708
Closed Access | Times Cited: 96
Christian U Blank, Minke W Lucas, Richard A. Scolyer, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1696-1708
Closed Access | Times Cited: 96
Showing 1-25 of 96 citing articles:
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma
Clara Martínez-Vila, Cristina Teixidó, Francisco Aya, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 861-861
Open Access | Times Cited: 1
Clara Martínez-Vila, Cristina Teixidó, Francisco Aya, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 861-861
Open Access | Times Cited: 1
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 12
Alexander M.M. Eggermont, Michal Kiciński, Christian U. Blank, et al.
European Journal of Cancer (2024) Vol. 211, pp. 114327-114327
Closed Access | Times Cited: 12
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
P.G.M. de Gooyer, Y.L. Verschoor, L.D.W. van den Dungen, et al.
Nature Medicine (2024)
Open Access | Times Cited: 6
P.G.M. de Gooyer, Y.L. Verschoor, L.D.W. van den Dungen, et al.
Nature Medicine (2024)
Open Access | Times Cited: 6
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Iris Nederlof, Olga I. Isaeva, Manon de Graaf, et al.
Nature Medicine (2024) Vol. 30, Iss. 11, pp. 3223-3235
Open Access | Times Cited: 6
Iris Nederlof, Olga I. Isaeva, Manon de Graaf, et al.
Nature Medicine (2024) Vol. 30, Iss. 11, pp. 3223-3235
Open Access | Times Cited: 6
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response
Christopher J.M. Williams, Allyson Peddle, Pashtoon Murtaza Kasi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 12, pp. 839-851
Closed Access | Times Cited: 6
Christopher J.M. Williams, Allyson Peddle, Pashtoon Murtaza Kasi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 12, pp. 839-851
Closed Access | Times Cited: 6
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Diwakar Davar, Robert M. Morrison, Amiran Dzutsev, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1898-1918.e12
Open Access | Times Cited: 5
Diwakar Davar, Robert M. Morrison, Amiran Dzutsev, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1898-1918.e12
Open Access | Times Cited: 5
Radiation Therapy for Melanoma and Merkel Cell Carcinoma in the Contemporary Era
Andrew Arifin, Devarati Mitra
Surgical Clinics of North America (2025)
Closed Access
Andrew Arifin, Devarati Mitra
Surgical Clinics of North America (2025)
Closed Access
Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
Axel Hauschild, Claus Garbe, Paolo A. Ascierto, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 12-14
Closed Access
Axel Hauschild, Claus Garbe, Paolo A. Ascierto, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. 12-14
Closed Access
Updates in Management for Local Regionally Advanced Squamous Cell Carcinoma
Norma E. Farrow, Danielle M. Bello
Surgical Clinics of North America (2025)
Closed Access
Norma E. Farrow, Danielle M. Bello
Surgical Clinics of North America (2025)
Closed Access
Role of Surgery for Metastatic Melanoma in the Era of Checkpoint Blockade
Vennila Padmanaban, Carlo M. Contreras
Surgical Clinics of North America (2025)
Closed Access
Vennila Padmanaban, Carlo M. Contreras
Surgical Clinics of North America (2025)
Closed Access
Current and emerging treatment options for BRAFV600-mutant melanoma
Anadil Javaid, Tobias Peres, Javier Pozas, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Anadil Javaid, Tobias Peres, Javier Pozas, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Female Oncofertility and Immune Checkpoint Blockade in Melanoma: Where Are We Today?
Cha Len Lee, Erika Martínez, Diego Malón, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 238-238
Open Access
Cha Len Lee, Erika Martínez, Diego Malón, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 238-238
Open Access
Neoadjuvant or perioperative immunotherapy for resectable melanoma: the need for biomarkers
Eva Ellebæk, Marco Donia, Inge Marie Svane
European Journal of Cancer (2025) Vol. 217, pp. 115257-115257
Closed Access
Eva Ellebæk, Marco Donia, Inge Marie Svane
European Journal of Cancer (2025) Vol. 217, pp. 115257-115257
Closed Access
A decade of progress and innovation in dermatology
Robert Gniadecki
Frontiers in Medicine (2025) Vol. 11
Open Access
Robert Gniadecki
Frontiers in Medicine (2025) Vol. 11
Open Access
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types
Axel Bex, Michael A.S. Jewett, Bryan Lewis, et al.
European Urology (2025)
Closed Access
Axel Bex, Michael A.S. Jewett, Bryan Lewis, et al.
European Urology (2025)
Closed Access
Neoadjuvant treatment in advanced resectable melanoma and the need for a predictive biomarker - is pathologic complete response (pCR) the answer?
Nathaniel R. Wilson, Christina V. Angeles, Tarek Haykal
The American Journal of Surgery (2025), pp. 116207-116207
Closed Access
Nathaniel R. Wilson, Christina V. Angeles, Tarek Haykal
The American Journal of Surgery (2025), pp. 116207-116207
Closed Access
Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
Suzanne L. Topalian, Drew M. Pardoll
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010833-e010833
Open Access
Suzanne L. Topalian, Drew M. Pardoll
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010833-e010833
Open Access
Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access
Acral Melanoma in Skin of Color: Current Insights and Future Directions: A Narrative Review
Emily R. Nadelmann, Ajay Singh, Matteo Abbruzzese, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 468-468
Open Access
Emily R. Nadelmann, Ajay Singh, Matteo Abbruzzese, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 468-468
Open Access
Navigating the landscape of immune checkpoint inhibitors and novel immunotherapies in melanoma: long-term outcomes, progress, and challenges
Sowmya Cheruvu, David McMahon, James Larkin
Expert Opinion on Biological Therapy (2025), pp. 1-12
Closed Access
Sowmya Cheruvu, David McMahon, James Larkin
Expert Opinion on Biological Therapy (2025), pp. 1-12
Closed Access
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?
B. Penninx, Michael Samson, John‐John B. Schnog
Cancer (2025) Vol. 131, Iss. 4
Closed Access
B. Penninx, Michael Samson, John‐John B. Schnog
Cancer (2025) Vol. 131, Iss. 4
Closed Access
Tumor immunology and immunotherapy for endometrial cancer
Kosuke Murakami, Shiki Takamura, Kazuhiro Kakimi, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-12
Open Access
Kosuke Murakami, Shiki Takamura, Kazuhiro Kakimi, et al.
Expert Opinion on Investigational Drugs (2025), pp. 1-12
Open Access
Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Nina Glassée, Michal Kiciński, et al.
EJC Skin Cancer (2025), pp. 100284-100284
Open Access
Oliver John Kennedy, Nina Glassée, Michal Kiciński, et al.
EJC Skin Cancer (2025), pp. 100284-100284
Open Access
Immune Checkpoint Inhibitors in the Treatment of Ocular Surface Cancers: A Review
Wenzhao Li, Wisam Najdawi, Omar Badla, et al.
Seminars in Ophthalmology (2025), pp. 1-11
Closed Access
Wenzhao Li, Wisam Najdawi, Omar Badla, et al.
Seminars in Ophthalmology (2025), pp. 1-11
Closed Access
Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028
Marco Donia, Henrik Jespersen, Mathilde Jalving, et al.
ESMO Open (2025) Vol. 10, Iss. 3, pp. 104295-104295
Closed Access
Marco Donia, Henrik Jespersen, Mathilde Jalving, et al.
ESMO Open (2025) Vol. 10, Iss. 3, pp. 104295-104295
Closed Access
